PureTech Health plc

NASDAQ:PRTC

Biotechnology

Healthcare
$17.38 +2.64%

+$0.45 today

Market cap
$423.09M
Beta
0.79
P/E (TTM)
-0.4
EPS (TTM)
-$45.37
52W Low $14.50High $19.92

Volume 0.01M

Average 0.01M

PRTC Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

PureTech Health plcNASDAQ: PRTC

Selling, General & Admin · Q4 FY2025 · quarter ended Dec 2025

Selling, general & admin turns positive

Q4 FY2025 selling, general & admin was $20M, compared with -$267K a year earlier. Over 3 fiscal years it compounded at -16.7% a year.

Context

  • Selling, general & admin amounted to 443.3% of revenue in FY2025, down 126.1 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 1 analysts of $443.51M (+2047.4%) for the fiscal year ending Dec 2026, a step up from the -24.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
$20M— QoQ
Last fiscal yearDec 2025
$20.65M-24.9% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7591.7%——
1 year-24.9%+2047.4%+2072.3 pp
3-year CAGR-16.7%+490.2%+506.8 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
20.65M USD
Year-over-year change
-24.9%
4-year CAGR
-9.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How PRTC compares with its peers on the latest reported figures

  • PRTC's FY2025 selling, general & admin of $20.65M is the 10th highest of the 11 companies compared; the peer median is $49.04M.
  • Its year-over-year change of -24.9% is the 10th highest of 11, against a peer median of +12.6%.
  • Selling, general & admin amounts to 443.3% of revenue for PRTC, versus a peer median of 153.6%.
PRTC Competitors Peer median
Selling, General & Admin for PRTC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AUTLAutolus Therapeutics plcLTM Mar 2026$142.24M +17.3%+60.5%153.6%
ADCTADC Therapeutics S.A.LTM Mar 2026$82.03M +32.5%—103.6%
ALMSAlumis Inc. Common StockLTM Jun 2026$77.08M +17.2%+94.2%1041.9%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$75.11M -30.1%+13.7%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$55.57M -17.1%+24.5%—
QSIQuantum-Si incorporatedLTM Mar 2026$42.51M -16.5%+1.9%2295.5%
SLDBSolid Biosciences Inc.LTM Mar 2026$40.91M +18.8%+10.3%—
BNTCBenitec Biopharma Inc.LTM Mar 2026$34.74M +87.8%+52.2%—
NGNENeurogene Inc.LTM Mar 2026$27.57M +8.0%+40.7%—
PRTCPureTech Health plcFY2025$20.65M -24.9%-16.7%443.3%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$18.69M +3.6%-6.4%126.4%
Peer median (excluding PRTC) $49.04M+12.6%+24.5%153.6%

Competitors are the stored peer set for PRTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.98M2.09M3.33M4.83M4.66M
Cost of Revenue110.47M152.43M4.93M3.57M3.36M
Gross Profit(100.49M)(136.82M)(1.6M)1.26M4.66M
Gross Margin-1007.0%-6546.2%-48.1%26.0%100.0%
Research & Development81.52M116.11M96.24M54.28M45.74M
Selling, General & Admin30.76M35.67M48.36M27.49M20.65M
Operating Expenses160.26M60.99M54.55M140.41M103.18M
Depreciation & Amortization7.24M8.89M4.93M3.57M3.35M
EBITDA26.7M(188.91M)(11.63M)37.38M(61.8M)
EBITDA Margin267.6%-9038.9%-349.2%774.3%-1326.5%
Operating Income(150.28M)(197.81M)(146.2M)(136.1M)(98.53M)
Operating Margin-1506.0%-9464.4%-4390.4%-2818.9%-2114.7%
Interest Income214K5.8M16.01M22.67M13.05M
Interest Expense4.71M3.95M13.49M10.04M45.78M
Other Income / Expenses91.33M105.02M110.1M159.87M(12.4M)
Income Before Tax(58.95M)(92.78M)(36.1M)23.77M(110.93M)
Pre-Tax Margin-590.8%-4439.4%-1084.2%492.4%-2380.9%
Income Tax Expense3.76M(55.72M)30.53M(4.01M)(842K)
Net Income(60.56M)(50.36M)(65.7M)53.51M(109.74M)
Net Margin-606.9%-2409.3%-1972.9%1108.3%-2355.4%
EPS (Basic)(2.10)(1.80)(2.40)2.00(46.00)
EPS (Diluted)(2.10)(1.80)(2.40)2.00(46.00)
Weighted Avg Shares28.66M27.97M27.63M26.97M2.41M
Weighted Avg Shares (Diluted)28.66M28.48M27.63M26.97M2.41M

PureTech Health plc

NASDAQ:PRTC

Intrinsic Alpha fair value

Locked

Current Price

$17.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.